Bulevirtide 在慢性乙型肝炎伴肝硬化患者中降低肝功能衰竭风险
Bulevirtide Linked to Less Decompensation in Chronic Hep D With Cirrhosis
一项欧洲回顾性研究显示,在慢性乙型肝炎伴肝硬化患者中,Bulevirtide 治疗显著降低了新发肝功能衰竭的风险,但对新发肝细胞癌的风险无显著影响。
研究发现,Bulevirtide 能降低慢性乙型肝炎伴肝硬化患者的肝功能衰竭风险,但对肝癌风险无显著影响。
— However, recently approved drug did not appear to reduce liver cancer risk in retrospective study
November 9, 2026 • 3 min read
In patients with chronic hepatitis delta (CHD) with cirrhosis, treatment with bulevirtide (Hepcludex) was associated with lower risk of liver decompensation, according to results from a European retrospective study.
Among more than 700 CHD patients with cirrhosis, those treated with bulevirtide had significantly lower rates of de-novo decompensation compared with untreated patients, with 3-year cumulative incidence rates of 3% versus 11.3%, respectively (P=0.001), reported Elisabetta Degasperi, MD, PhD, of the Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan.
On the other hand, there was no significant difference in 3-year de-novo hepatocellular carcinoma (HCC) rates between the two cohorts (7.3% for treated patients vs 3.6% for untreated patients, P=0.86).
"In chronic hepatitis delta patients with cirrhosis, a 36-month course of bulevirtide monotherapy reduces decompensation, but not HCC, compared to historical pooled untreated cohorts," Degasperi said at the annual Liver Meeting in Denver, sponsored by the American Association for the Study of Liver Diseases.
"Chronic hepatitis delta is the most severe form of viral hepatitis, resulting in fast progression to cirrhosis and its complications, such as hepatocellular carcinoma and decompensation," Degasperi said, in explaining the rationale behind the study.
She pointed out that bulevirtide has been approved by the FDA for treatment of CHD in adults without cirrhosis or with compensated cirrhosis, and that in phase II and III clinical trials and real-world studies, bulevirtide monotherapy has achieved higher rates of virological and biochemical responses in patients with cirrhosis.
"However, the impact of bulevirtide treatment on hard clinical outcomes remains scarcely defined," she added.
Here, CHD patients with cirrhosis receiving bulevirtide monotherapy for up to 3 years in a retrospective European cohort study were compared with pooled data from two cohorts not treated with bulevirtide. The study endpoints were the incidence of liver-related events (decompensation and HCC), death, or liver transplantation.
The study included a total of 729 patients (431 treated with bulevirtide and 298 untreated controls). There were some significant differences in baseline characteristics between the cohorts (including age and sex), but inverse probability treatment weighing (IPTW) was used to balance the groups.
Among patients treated with bulevirtide monotherapy, 72% achieved virological response, 70% biochemical response, and 54% a combined response at 3 years.
During the course of the study, there were a total of 36 de novo liver-related events in bulevirtide-treated patients (12 decompensation and 24 HCC) and 32 in untreated patients (24 decompensation and eight HCC).
In the IPTW-adjusted Cox regression analysis, bulevirtide-treated patients had significantly lower risk of developing liver-related events compared with untreated controls (HR 0.69, 95% CI 0.49-0.99, P=0.04) or decompensation (HR 0.66, 95% CI 0.44-0.98, P=0.03). These results were confirmed by the IPTW-adjusted competing risks regression model.
Conversely, the risk of HCC was similar between the two groups (HR 0.83, 95% CI 0.50-1.36, P=0.46).
Among patients treated with bulevirtide, lower baseline albumin values independently predicted liver decompensation (HR 0.17, 95% CI 0.07-0.39, P=0.001), while independent predictors of HCC in this group also included lower albumin (HR 0.22, 95% CI 0.11-0.44, P<0.001), as well as older age (HR 1.05, 95% CI 1.01-1.09, P=0.01) and male sex (HR 3.72, 95% CI 1.39-9.91, P=0.01).
Regarding overall survival (OS), "we did not see any significant difference between bulevirtide-treated and untreated patients, and this was also confirmed in the adjusted analysis," Degasperi observed. The 3-year OS rate was 95.2% with bulevirtide and 96.2% among untreated patients (P=0.63).
However, "if you concentrate on the features of events, we can see that most events leading to liver transplant, and also death, in the bulevirtide-treated cohort were HCC related, while in untreated patients, end-stage liver disease was the most frequent liver-related event leading to death and liver transplant," she pointed out.
Specifically, there were a total of 16 deaths or liver transplantations in the bulevirtide arm, 12 of which were HCC related, while seven of the nine deaths or liver transplantations in the untreated cohort were related to end-stage liver disease.
"Of course, additional studies in cohorts with extended follow-up are needed in order to confirm these data," she concluded.
来源:MedPage Today · medpagetoday.com